Share

October 13, 2015; 85 (15) Video NeuroImages

Iridodonesis as a cause of recurrent vertigo

Hagen Kunte, Friedemann Paul, Florence Pache, Jan Dörr, Judith Bellmann-Strobl, Lutz Harms, Golo Kronenberg
First published October 12, 2015, DOI: https://doi.org/10.1212/WNL.0000000000002025
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
642

Share

Article Information

vol. 85 no. 15 1353
DOI: 
https://doi.org/10.1212/WNL.0000000000002025
PubMed: 
26459941
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published October 12, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology

Author Disclosures

    1. Hagen Kunte, MD,
    2. Friedemann Paul, MD,
    3. Florence Pache, MD,
    4. Jan Dörr, MD,
    5. Judith Bellmann-Strobl, MD,
    6. Lutz Harms, MD and
    7. Golo Kronenberg, MD
  1. Hagen Kunte, MD,
    2. Scientific Advisory Boards:

    1. On advisory board for Teva and Genzyme.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I received personal compensation from Biogen, Genzyme, Novartis and Teva for speaking. I received travel Support from Biogen, Genzyme, Norvartis and Teva.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Friedemann Paul, MD,
    3. Scientific Advisory Boards:

    1. Novartis OCTIMS study steering committee MedImmune steering committee

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono

    Editorial Boards:

    1. Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. consultancies for SanofiGenzyme, BiogenIdec, MedImmune

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono

    Research Support, Government Entities:

    1. German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Florence Pache, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Commercial: Travel grant from Genzyme, a Sanofi Company (2) Commercial: Travel grant from Bayer (3) Commercial: Travel grant from Biogene Idec (4) Non-profit: Travel grant from ECTRIMS ( European Committee for Treatment and Research in Multiple Sclerosis)

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) governmental grant to Friedemann Paul- used for 50 % of my employment: KKNMS- Bundesministerium f?r Bildung und Forschung- governmental support- Ministry in Germany (“) commercial grant to Friedemann Paul- used for a short time part employment to me: Novartis- no significant conflict of interest

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Jan Dörr, MD,
    5. Scientific Advisory Boards:

    1. Compensation for serving on advisory board by Bayer (2015), Novartis (2015), Teva (2013, 2014), Genzyme (2013, 2014)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Travel Funding by Novartis (2015, 2014, 2013), Genzyme (2015), and Bayer (2014).Speaker Honoraria by Novartis (2014, 2013), Teva (2013), Sanofi/Genzyme (2013, 2014, 2015), Biogen-idec (2014)

    Editorial Boards:

    1. BMC Neurology, Associate Editor, 2015

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support by Novartis (2013, 2014, 2015) and Bayer (2013, 2014, 2015)

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Judith Bellmann-Strobl, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. speaking fees and travel grants from Bayer Healthcare, sanofi-aventis/Genzyme, and Teva Pharmaceuticals

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Lutz Harms, MD and
    7. Scientific Advisory Boards:

    1. I received personal compensation from Novartis, Sanofi/Genzyme, Roch and Biogen Idec as a member of advisory board.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I received personal compensation from Novartis, Biogen- Idec, Merck-Serono and Bayer Health Care for speaking. I received travel support from Bayer Health Care, Novartis,Teva and Biogen-Idec.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Golo Kronenberg, MD
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Co-host of a symposium on ADHD and ADHD treatment; speaker honoraria from Eli Lilly (commercial). Not relevant to the topic of the study.

    Editorial Boards:

    1. Review Editor for Frontiers Journals, No Compensation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From NeuroCure Clinical Research Center (H.K., F. Paul, F. Pache, J.D., J.B.-S.) and Charité Center 15 for Neurology, Neurosurgery and Psychiatry (L.H., G.K.), Charité-Universitätsmedizin Berlin; and Experimental and Clinical Research Center (J.B.-S.), Max Delbrück Center for Molecular Medicine, Berlin, Germany.
  1. Correspondence to Dr. Kunte: hagen.kunte{at}charite.de
View Full Text

Article usage

Article usage: October 2015 to February 2023

AbstractFullPdfSource
Oct 201538892132Highwire
Nov 2015582731Highwire
Dec 2015295810Highwire
Jan 201615119Highwire
Feb 201617813Highwire
Mar 201612614Highwire
Apr 20161177Highwire
May 201627617Highwire
Jun 2016869Highwire
Jul 20164716Highwire
Aug 20161088Highwire
Sep 2016914Highwire
Oct 20161388Highwire
Nov 2016777Highwire
Dec 20161730Highwire
Jan 2017900Highwire
Feb 20171768Highwire
Mar 20171014Highwire
Apr 20171713Highwire
May 20171312Highwire
Jun 20171028Highwire
Jul 20171003Highwire
Aug 2017900Highwire
Sep 2017815Highwire
Oct 2017721Highwire
Nov 20171064Highwire
Dec 2017271Highwire
Jan 20181130Highwire
Feb 20181131Highwire
Mar 20180162Highwire
Apr 20180101Highwire
May 20181183Highwire
Jun 20180171Highwire
Jul 20180262Highwire
Aug 20180172Highwire
Sep 20180160Highwire
Oct 20180415Highwire
Nov 20180352Highwire
Dec 20182389Highwire
Jan 20190484Highwire
Feb 20191462Highwire
Mar 20192317Highwire
Apr 20190407Highwire
May 20193415Highwire
Jun 20191353Highwire
Jul 20190525Highwire
Aug 20190305Highwire
Sep 20191251Highwire
Oct 20191684Highwire
Nov 2019811412Highwire
Dec 20190803Highwire
Jan 20204746Highwire
Feb 20200815Highwire
Mar 202001013Highwire
Apr 20200333Highwire
May 20200574Highwire
Jun 202011584Highwire
Jul 20200542Highwire
Aug 20202487Highwire
Sep 20200633Highwire
Oct 20200378Highwire
Nov 20200355Highwire
Dec 20201753Highwire
Jan 20210786Highwire
Feb 20211655Highwire
Mar 20212737Highwire
Apr 20211672Highwire
May 20214467Highwire
Jun 20215429Highwire
Jul 202127712Highwire
Aug 20211487Highwire
Sep 20210529Highwire
Oct 202123318Highwire
Nov 202104215Highwire
Dec 20210353Highwire
Jan 20221546Highwire
Feb 20222576Highwire
Mar 20220464Highwire
Apr 20220586Highwire
May 202215814Highwire
Jun 20220483Highwire
Jul 20220665Highwire
Aug 20220534Highwire
Sep 202209613Highwire
Oct 20223807Highwire
Nov 202201113Highwire
Dec 20221563Highwire
Jan 20231681Highwire
Feb 202311004Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles